Clinical MicrobiologyResearch Center, Ilam University of Medical Sciences, Ilam, Iran.
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Glob Antimicrob Resist. 2021 Jun;25:48-59. doi: 10.1016/j.jgar.2021.02.017. Epub 2021 Mar 5.
The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent.
耐药结核病（TB）的发展是全球的主要威胁。根据世界卫生组织（WHO）的报告，估计每年有超过 500,000 例新的耐药结核病病例。此外，来自世界不同国家的报告显示，耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）的情况令人震惊。因此，需要新的结核病治疗方案。贝达喹啉（BDQ）是一种新型抗结核药物，对敏感和耐药结核病均具有显著的最低抑菌浓度（MIC）。此外，BDQ 最近被批准用于治疗耐多药结核病。本综述总结了有关 BDQ 耐药性的现有数据，描述了其抗菌特性，并为该新型抗结核药物的临床应用提供了新的视角。
